Published in final edited form as:

J Am Chem Soc. 2011 March 16; 133(10): 3230–3233. doi:10.1021/ja1083915.

Synthesis of a Trimeric gp120 Epitope Mimic Conjugated to a T-Helper Peptide to Improve Antigenicity

Joan G. Go¹, Lieza M. Danan-Leon², Jessica A. Hoch, Aemro Kassa³, Indresh Srivastava, David Davis⁴, and Jacquelyn Gervay-Hague^{*}

Chemistry Department, University of California at Davis, One Shields Avenue, Davis, CA 95616 USA, Department of Molecular and Cellular Biology, Campus Mass Spectrometry Facility, University of California at Davis, 9 Hutchison Hall, One Shields Avenue, Davis, CA 95616, and Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands. Novartis Vaccines and Diagnostics, Inc., 45 Sidney Street, 3105, Cambridge, MA 02139

Abstract

A fully synthetic trivalent mimotope of gp120 conjugated to pan allelic HLA DR binding epitope (PADRE) was prepared using solid phase peptide synthesis (SPPS) and optimized copper-catalyzed azide alkyne cycloaddition (CuAAC). The methodology efficiently provides chemically uniform heteromultimeric peptide constructs, with features of enhanced binding, avidity and specificity towards an established HIV neutralizing human antibody, MAb b12. The versatile synthetic strategy serves as a powerful platform for the development of synthetic peptides as potential HIV-1 vaccine candidates.

Despite the tremendous success brought about by combined antiretroviral therapy in reducing HIV-1 related mortality worldwide, an effective and safe HIV-1 vaccine is still needed to ultimately eradicate the virus and control the AIDS pandemic.^{1,2} A promising vaccine strategy centers on the design and synthesis of antigenic peptides that mimic HIV envelope protein epitopes.^{3–7} The expectation is that these so called mimotopes⁸ would be capable of eliciting an immune response leading to the production of broadly neutralizing antibodies. HIV envelope protein has several conserved neutralizing epitopes, which are defined by human monoclonal antibodies (MAb). We have focused our attention on MAb b12, which recognizes a discontinuous conformational epitope of HIV envelope.^{9,10} While phage-display technology has proven effective for the selection of mimotopes, soluble peptide constructs are only weakly immunogenic compared to fusion proteins with the same sequence.⁶ Attenuated immunogenicity has been attributed to the intrinsic flexibility, relatively small size and limited binding interface of monomeric peptides.^{11,12} Moreover, phage encoded peptides are displayed in multiple copies as part of a filamentous protein coat suggesting that multimeric mimotope constructs may be required for a potent immune response.^{3,13–15} Our research efforts focus on developing a chemical synthesis platform for the construction of chemically uniform multimeric mimotopes with improved antigenicity as part of a larger program directed toward vaccine development.

gervay@chem.ucdavis.edu.

¹Chemistry Department, UC Davis

²Molecular and Cellular Biology Department, UC Davis

³Novartis Vaccines and Diagnostics, Inc

⁴Biomedical Primate Research Center

Supporting Information Available: Experimental details on the synthesis of the peptide, linkers and multimerization, including SPR experiments. This material is available free of charge via the Internet at <http://pubs.acs.org>.

New mimotopes are continually emerging,^{16–19} however many of these peptides are predicted to be hydrophobic limiting the types of formulations in which they can be used. Our initial studies have focused on a mimotope that is predicted to be water-soluble based upon the hydrophobicity score.²⁰ The 15-mer peptide, with the sequence NWPRWEEFVDKHSS, was identified using MAb IgG1 b12-selected phage and gp120 competition.²¹ The potent broadly neutralizing anti-HIV MAb b12^{22–24} is known to bind to a discontinuous epitope overlapping the CD4-binding site of the HIV-1 envelope surface protein, gp120.^{9,10} Because gp120 is known to be trimeric on the viral surface, the design features three copies of the mimotope. In addition to stimulating an antigen specific B-cell response with trimeric mimotope,²⁵ an immunogenic T-helper (T_H) epitope is also included. Conjugation to pan allelic HLA DR binding epitope (PADRE), a known T_H epitope with the sequence aKXVAAWTLKAAa, is intended to stimulate T_H cells for a sustained antibody immune response, Figure 1.^{26–29}

There are a myriad of synthetic approaches available to achieve multivalent presentation of biologically active ligands including the multiple antigenic peptide (MAP) system.¹⁴ While this methodology allows elaborate synthetic assembly of multiple peptides on the core, difficulties in achieving quantitative couplings and incomplete amino acid side-chain deprotection arise in sterically crowded dendrimer networks, resulting in undefined structures and heterogeneous products.³⁰ Meijer and co-workers have reported an attractive alternative approach using native chemical ligation (NCL) of peptides derived from phage technology by rebuilding the phage's multivalent architecture using well-designed dendritic wedges as synthetic scaffolds.³¹ One major limitation of NCL, while also being one of the most powerful tools in peptide and protein chemical synthesis,³² is the need for an N-terminal cysteine-containing peptide. Concerns over the presence of cysteine creating unpredictable conformational changes of the peptide and/or undesirable conjugates to native peptides have stimulated alternative synthetic platforms.³³

Our approach utilizes a well-known bioorthogonal strategy, copper-catalyzed azide-alkyne 1,3 dipolar cycloaddition (CuAAC) reaction or click chemistry.^{34–39} The non-native, highly selective and exergonic reaction of azide and alkyne functionalities,^{40–42} coupled with the peptidomimetic nature of the triazole cycloaddition product and its proteolytic stability^{43–45} have proven to be attractive features of CuAAC. But this methodology is not without its limitations, as copper catalysis can lead to unwanted side reactions particularly in biological settings.^{46–48} Nevertheless, our previous success with conjugating recombinant antibody fragment, scFv (~25kDa protein), to form divalent scFv led us in this direction. Formation of di-scFv involves the use of an azide and alkyne PEG linker to functionalize the protein in preparation for ligation via the cycloaddition reaction.⁴⁹ This methodology also allows for the construction of hetero-multimers, wherein one arm can be conjugated to a different peptide such as PADRE. Another advantage of this approach is that the azide and alkyne functionalized peptides have similar solubility profiles resulting in a homogeneous reaction medium and faster reaction rates.⁵⁰

We initiated the synthesis of azide functionalized mimotope and trialkyne PADRE using solid phase peptide synthesis (SPPS) with conventional Fmoc-tBu orthogonal protection and a versatile tentagel resin with a hydroxymethylbenzoic acid (HMBA) linker (Scheme 1). 1-(Mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole (MSNT) and 1-methyl imidazole (MeIm) were used as coupling agents to incorporate the first amino acid residue⁵¹ followed by iterative microwave-assisted Fmoc deprotection and amide coupling using 1-hydroxybenzotriazole (HOBt)/N,N'-diisopropylcarbodiimide (DIC) as activators.⁵² To functionalize the PADRE and the mimotope, the free amino N-termini of the protected peptides on bead were coupled with trialkyne PEG linker (**1**) and azide PEG linker (**2**), conditions and coupling agents to give resin bound functionalized peptides. Amino acid

protecting groups were removed by treating the resin with 95% TFA, 2.5% triisopropylsilane (TIPS) and 2.5% H₂O. Cleavage from the resin was accomplished with 1:3 1M NaOH:dioxane followed by immediate neutralization using 1M HCl (Scheme 1). Desalting was achieved using Sep-Pak® C18 providing the crude peptides, which were subjected to HPLC purification to give >90% pure trialkyne functionalized PADRE (**3**) and azide functionalized mimotope (**4**) as confirmed by MS (see supporting information).

The most convenient CuAAC reaction conditions involve the use of CuSO₄ and sodium ascorbate as a reductant along with an appropriate chelating ligand that maintains the Cu(I) oxidation state.^{53–55} Unfortunately, our initial experiments utilizing bathophenanthrolinedisulfonic acid as a ligand were not fruitful, as only oxidized peptides were retrieved, even under oxygen free conditions. However we were fortunate to learn that Finn and co-workers have recently offered a solution to over oxidation with the use of tris(3-hydroxypropyltriaazoylmethyl)amine (THPTA) (**5**), which serves as a scavenger for radical species, and an additive, aminoguanidine, to prevent crosslinking and aggregation products.⁵⁶ We were hopeful that this approach would be well suited for mimotope multimerization given the high tryptophan content of our peptides.

We followed the Finn protocol by reacting **3** and **4** with 5 mM sodium ascorbate, 5 mM aminoguanidine, 0.1 mM respectively, using the same microwave irradiation CuSO₄, and 0.5 mM THPTA ligand (**5**) in 10 mM phosphate buffer at pH = 7.4 containing 5% DMSO for 18 h (Scheme 1). After desalting and buffer exchange procedures, lyophilized material gave 3.2 mg (70%) of a white fluffy solid that was analyzed by high resolution MS. After deconvolution, the spectrum gave an observed mass monoisotopic peak of 8386.9900 (theoretical mass = 8387.0104) as seen from Figure S4, which corresponds to the desired trimeric mimotope-PADRE cycloaddition product **6**. Recovered excess starting materials showed minimal oxidation, even after overnight reaction.

We then initiated surface plasmon resonance (SPR) experiments to compare the binding affinity and specificity of the trimeric mimotope-PADRE construct (**6**) to the HIV broadly neutralizing MAb b12. To validate the effect of valency, molar concentrations were adjusted to equalize the number of ligands or the total binding sites in solution. A blank chip was used as a reference cell for all sensorgrams shown in Figure 2. Detailed information on the SPR experiments can be found in the supporting information. As shown in Figure 2a, trimeric mimotope-PADRE (**6**) showed the fastest on-rate featuring enhanced binding towards MAb b12 compared to the monomeric mimotope and PADRE, which served as a negative control. During dissociation, ~ 300–660 s, construct **6** exhibits a significant analyte response with a very slow off-rate, which is a clear indication of increased avidity.⁵⁷

To evaluate binding specificity for MAb b12, the peptides were screened against a random anti-HIV antibody (MAb 48d), which was captured to equivalent levels (10,000 RU) on a CM5 chip. Comparison of the increased response from the sensorgram towards MAb b12 binding (Figure 2a) to the lack of any response from the sensorgrams towards MAb 48d binding (Figure 2b) clearly indicates that trimeric mimotope-PADRE **6** binds specifically to MAb b12. Taken together these data demonstrate that trimeric mimotope-PADRE **6** shows increased binding, avidity and specificity towards MAb b12, which may be attributed to the multivalent presentation of mimotope.

Presented herein is a versatile synthetic platform for preparing multivalent peptide constructs having two different peptide components. The high efficiency of the 1,3 dipolar cyclization under conditions that alleviate oxidation of susceptible amino acid side chains was critical to the success of this approach. While the hetero-multivalent design presented here includes peptides designed to stimulate both B-cell and T_H cell immune response, one

could conceivably join any combination of peptides using this same strategy providing a powerful tool for structure activity relationship analyses. We look forward to reporting the results of such studies in the near future.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by The National Institutes of Health HIVRAD IPO1 AI066287. Funding for the NMR spectrometers was provided by NIH RR11973.

References

1. Fauci AS. *Nature*. 2008; 453:289. [PubMed: 18480799]
2. Barouch DH. *Nature*. 2008; 455:613. [PubMed: 18833271]
3. Smith GP, Petrenko VA. *Chem Rev*. 1997; 97:391. [PubMed: 11848876]
4. Keller PM, Arnold BA, Shaw AR, Tolman RL, Van Middlesworth F, Bondy S, Rusiecki VK, Koenig S, Zolla-Pazner S, Conard P, Emini EA, Conley AJ. *Virology*. 1993; 193:709. [PubMed: 7681612]
5. Scala G, Chen X, Liu W, Telles JN, Cohen OJ, Vaccarezza M, Igarashi T, Fauci AS. *J Immunol*. 1999; 162:6155. [PubMed: 10229859]
6. Zwick MB, Bonnycastle LLC, Menendez A, Irving MB, Barbas CF III, Parren PWHI, Burton DR, Scott JK. *J Virol*. 2001; 75:6692. [PubMed: 11413337]
7. Irving MB, Pan O, Scott JK. *Curr Opin Chem Biol*. 2001; 5:314. [PubMed: 11479124]
8. Geysen HM, Rodda SJ, Mason TJ. *Molecular Immunology*. 1986; 23:709. [PubMed: 2432410]
9. Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR. *J Virol*. 2003; 77:642. [PubMed: 12477867]
10. Pantophlet R, Burton DR. *Annu Rev Immunol*. 2006; 24:739. [PubMed: 16551265]
11. Sakarellos-Daitsiotis M, Krikorian D, Panou-Pomonis E, Sakarellos C. *Curr Top Med Chem*. 2006; 6:1715. [PubMed: 17017953]
12. Ross AL, Brave A, Scarlatti G, Manrique A, Buonaguro L. *Lancet Infect Dis*. 2010; 10:305. [PubMed: 20417413]
13. Scott JK, Smith GP. *Science*. 1990; 249:386. [PubMed: 1696028]
14. Tam JP. *Proc Natl Acad Sci U S A*. 1988; 85:5409. [PubMed: 3399498]
15. Mammen M, Choi S-K, Whitesides GM. *Angew Chem Int Ed*. 1998; 37:2754.
16. Chen X, Scala G, Quinto I, Liu W, Chun TW, Justement JS, Cohen OJ, van Cott TC, Iwanicki M, Lewis MG, Greenhouse J, Barry T, Venzon D, Fauci AS. *Nat Med*. 2001; 7:1225. [PubMed: 11689887]
17. Humbert M, Antoni S, Brill B, Landersz M, Rodes B, Soriano V, Wintergerst U, Knechten H, Staszewski S, von Laer D, Dittmar MT, Dietrich U. *Eur J Immunol*. 2007; 37:501. [PubMed: 17236253]
18. Dieltjens T, Willems B, Coppens S, Van Nieuwenhove L, Humbert M, Dietrich U, Heyndrickx L, Vanham G, Janssens W. *J Virol Methods*. 2010; 169:95. [PubMed: 20637241]
19. Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny MK, Zolla-Pazner S, Kong XP. *Nat Struct Mol Biol*. 2010; 17:955. [PubMed: 20622876]
20. Kyte J, Doolittle RF. *J Mol Biol*. 1982; 157:105. [PubMed: 7108955]
21. Boots LJMPM, Arnold BA, Keller PM, Gorny MK, Zolla-Pazner S, Robinson JE, Conley AJ. *AIDS Res Hum Retrov*. 1997; 13:1549.
22. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al. *Science*. 1994; 266:1024. [PubMed: 7973652]

23. Kessler JA 2nd, McKenna PM, Emini EA, Chan CP, Patel MD, Gupta SK, Mark GE 3rd, Barbas CF 3rd, Burton DR, Conley AJ. *AIDS Res Hum Retrov.* 1997; 13:575.
24. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF 3rd, Burton DR, Ho DD. *J Virol.* 1995; 69:6609. [PubMed: 7474069]
25. Purcell AW, McCluskey J, Rossjohn J. *Nat Rev Drug Discov.* 2007; 6:404. [PubMed: 17473845]
26. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A, Grey HM. *Immunity.* 1994; 1:751. [PubMed: 7895164]
27. del Guercio M-F, Alexander J, Kubo RT, Arrhenius T, Maewal A, Appella E, Hoffman SL, Jones T, Valmori D, Sakaguchi K, Grey HM, Sette A. *Vaccine.* 1997; 15:441. [PubMed: 9141216]
28. Alexander J, del Guercio M-F, Maewal A, Qiao L, Fikes J, Chesnut RW, Paulson J, Bundle DR, DeFrees S, Sette A. *J Immunol.* 2000; 164:1625. [PubMed: 10640784]
29. Alexander J, Guercio M-Fd, Frame B, Maewal A, Sette A, Nahm MH, Newman MJ. *Vaccine.* 2004; 22:2362. [PubMed: 15193395]
30. De Oliveira E, Villen J, Giralt E, Andreu D. *Bioconjugate Chem.* 2003; 14:144.
31. Helms BA, Reulen SW, Nijhuis S, de Graaf-Heuvelmans PT, Merckx M, Meijer EW. *J Am Chem Soc.* 2009; 131:11683. [PubMed: 19642697]
32. Dawson PE, Muir TW, Clark-Lewis I, Kent SB. *Science.* 1994; 266:776. [PubMed: 7973629]
33. Yang R, Pasunooti KK, Li F, Liu XW, Liu CF. *J Am Chem Soc.* 2009; 131:13592. [PubMed: 19728708]
34. Kolb HC, Finn MG, Sharpless KB. *Angew Chem Int Ed.* 2001; 40:2004.
35. Lutz JF. *Angew Chem Int Ed.* 2007; 46:1018.
36. Meldal M, Tornoe CW. *Chem Rev.* 2008; 108:2952. [PubMed: 18698735]
37. Tornoe CW, Christensen C, Meldal M. *J Org Chem.* 2002; 67:3057. [PubMed: 11975567]
38. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. *Angew Chem Int Ed.* 2002; 41:2596.
39. Prescher JA, Bertozzi CR. *Nat Chem Biol.* 2005; 1:13. [PubMed: 16407987]
40. Lewis WG, Green LG, Grynszpan F, Radic Z, Carlier PR, Taylor P, Finn MG, Sharpless KB. *Angew Chem Int Ed.* 2002; 41:1053.
41. Mocharla VP, Colasson B, Lee LV, Roper S, Sharpless KB, Wong CH, Kolb HC. *Angew Chem Int Ed.* 2005; 44:116.
42. Whiting M, Muldoon J, Lin YC, Silverman SM, Lindstrom W, Olson AJ, Kolb HC, Finn MG, Sharpless KB, Elder JH, Fokin VV. *Angew Chem Int Ed.* 2006; 45:1435.
43. Tornoe CW, Sanderson SJ, Mottram JC, Coombs GH, Meldal M. *J Comb Chem.* 2004; 6:312. [PubMed: 15132590]
44. Brik A, Alexandratos J, Lin YC, Elder JH, Olson AJ, Wlodawer A, Goodsell DS, Wong CH. *Chembiochem.* 2005; 6:1167. [PubMed: 15934050]
45. Bock VD, Speijer D, Hiemstra H, van Maarseveen JH. *Org Biomol Chem.* 2007; 5:971. [PubMed: 17340013]
46. Link AJ, Tirrell DA. *J Am Chem Soc.* 2003; 125:11164. [PubMed: 16220915]
47. Agard NJ, Prescher JA, Bertozzi CR. *J Am Chem Soc.* 2004; 126:15046. [PubMed: 15547999]
48. Lutz JF. *Angew Chem Int Ed.* 2008; 47:2182.
49. Natarajan A, Du W, Xiong CY, DeNardo GL, DeNardo SJ, Gervay-Hague J. *Chem Commun.* 2007:695.
50. Foot JS, Lui FE, Kluger R. *Chem Commun.* 2009:7315.
51. Blankemeyer-Menge B, Nimtz M, Frank R. *Tetrahedron Lett.* 1990; 31:1701.
52. Bacsa B, Kappe CO. *Nat Protoc.* 2007; 2:2222. [PubMed: 17853879]
53. Chan TR, Hilgraf R, Sharpless KB, Fokin VV. *Org Lett.* 2004; 6:2853. [PubMed: 15330631]
54. Lewis WG, Magallon FG, Fokin VV, Finn MG. *J Am Chem Soc.* 2004; 126:9152. [PubMed: 15281783]
55. Gupta SS, Kuzelka J, Singh P, Lewis WG, Manchester M, Finn MG. *Bioconjugate Chem.* 2005; 16:1572.
56. Hong V, Presolski SI, Ma C, Finn MG. *Angew Chem Int Ed.* 2009; 48:9879.

57. Arranz-Plaza E, Tracy AS, Siriwardena A, Pierce JM, Boons GJ. *J Am Chem Soc.* 2002; 124:13035. [PubMed: 12405830]

Figure 1.
Design of trimeric mimotope-PADRE immunogen.

Figure 2.

Direct binding of construct **6**, mimotope and PADRE to (a) MAb b12 and (b) MAb 48d as shown by SPR. Sensorgram comparisons show enhanced binding, valency effect and specificity of the trimeric mimotope-PADRE **6** towards MAb b12.

Scheme 1.
General scheme for the construction of trimeric mimotope-PADRE using SPPS and CuAAC reaction.